Physician profile
Robert C Ladd
NPI 1558334839
$687.19
in general payments reported to CMS, 2019-2025
12 companies · $80.97 in 2025
The $80.97 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.74 · 2021: $249 · 2022: $104 · 2023: $127 · 2024: $69.14 · 2025: $80.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $338.74 | 2020-2025 | Evenity, Prolia |
| Abbvie INC. | $89.48 | 2021-2024 | |
| Mylan Specialty L.P. | $41.28 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $34.63 | 2025 | Airsupra |
| Lilly USA, LLC | $33.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.62 | 2021-2022 | |
| Dexcom, INC. | $17.29 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2023 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $14.27 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $14.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.